// App-Quantinova.ai

PO1020 : Once-Weekly Exenatide Effects on eGFR Slope and Urine Albumin-to-Creatinine Ratio (UACR) as a Function of Baseline UACR: An EXSCEL Post Hoc Analysis

Researchers

Presenter

  • Clegg Lindsay

Principal Investigators

  • Aart van der

  • Penland RobertC

  • Boulton DavidW

  • Sjostrom David

  • Mentz RobertJ

  • Rury Holman

  • L Heerspink HiddoJan

Medical Centers

  • Clinical Pharmacology & Quantitative Pharmacology R&D AstraZeneca Gaithersburg Maryland United States

  • Clinical Psychology, University of Groningen, Groningen, Netherlands

  • Clinical Pharmacology & Quantitative Pharmacology R&D AstraZeneca Boston Massachusetts United States

  • Late-stage Development CVRM BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden

  • Duke University and Duke Clinical Research Institute Duke University School of Medicine Durham North Carolina United States

  • Diabetes Trials Unit, Univ of Oxford, Oxford, United Kingdom

  • Clinical Psychology, University of Groningen, Groningen, Netherlands

Locations

  • United States

  • Netherlands

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Exenatide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved